Wellington Management Group LLP Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Wellington Management Group LLP decreased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 77.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,111 shares of the company's stock after selling 145,895 shares during the period. Wellington Management Group LLP's holdings in IDEAYA Biosciences were worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its stake in IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company's stock valued at $400,297,000 after acquiring an additional 1,365,570 shares during the period. Janus Henderson Group PLC raised its holdings in shares of IDEAYA Biosciences by 26.7% during the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company's stock worth $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. State Street Corp lifted its position in IDEAYA Biosciences by 15.4% during the third quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after purchasing an additional 443,640 shares during the period. Logos Global Management LP boosted its holdings in IDEAYA Biosciences by 13.3% in the second quarter. Logos Global Management LP now owns 1,700,000 shares of the company's stock valued at $59,687,000 after purchasing an additional 200,000 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new stake in IDEAYA Biosciences during the 3rd quarter worth about $42,681,000. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Up 3.3 %

Shares of IDEAYA Biosciences stock traded up $0.82 during mid-day trading on Friday, reaching $25.61. 1,937,098 shares of the stock traded hands, compared to its average volume of 870,979. The business has a 50-day moving average of $28.38 and a 200 day moving average of $34.10. The stock has a market capitalization of $2.21 billion, a PE ratio of -10.99 and a beta of 0.79. IDEAYA Biosciences, Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.03. During the same period in the previous year, the business posted ($0.46) earnings per share. On average, equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IDYA. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a report on Tuesday. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Oppenheimer reaffirmed an "outperform" rating and set a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Wedbush reissued an "outperform" rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday. Finally, Citigroup cut their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 27th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $53.67.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.